LSTA · Lisata Therapeutics Inc
United States · RS rating 4 · As of 2026-10-14
| Price | 1.02 USD |
|---|---|
| 1-day change | -5.6% |
| RS rating (overall / 1M / 3M / 12M) | 4 / 5 / 2 / 12 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 13 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +36.0% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +79.8% |
| Market cap (USD) | $30.1M |